Literature DB >> 18332238

Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.

Maarten Uyttenboogaart1, Marcus W Koch, Karen Koopman, Patrick C A J Vroomen, Jacques De Keyser, Gert-Jan Luijckx.   

Abstract

BACKGROUND: There is some uncertainty whether prior use of antiplatelet (AP) drugs increases the risk of symptomatic intracerebral hemorrhage (SICH) and influences functional outcome in patients with ischemic stroke treated with intravenous thrombolysis.
OBJECTIVE: To assess whether prior use of AP drugs is related to outcome following intravenous tissue plasminogen activator therapy in patients with ischemic stroke. DESIGN, SETTING, AND PATIENTS: A single-center prospective observational cohort study of the relation between prior AP therapy, occurrence of SICH, and functional outcome of consecutive patients with ischemic stroke undergoing intravenous thrombolysis with tissue plasminogen activator in a university hospital between April 1, 2002, and November 30, 2006. MAIN OUTCOME MEASURES: The occurrence of SICH and favorable outcome reflecting independence defined as a modified Rankin Scale score of 2 or lower at 3 months.
RESULTS: Of the 301 patients who received intravenous tissue plasminogen activator, 89 used AP drugs prior to thrombolysis. Symptomatic intracerebral hemorrhage occurred in 12 patients (13.5%; 95% confidence interval, 7.8%-22.3%) who had received AP drugs and in 6 patients (2.8%; 95% confidence interval, 1.2%-6.2%) without prior AP therapy (P = .001). Multivariate analysis revealed that prior AP therapy was an independent predictor of SICH (odds ratio, 6.0; 95% confidence interval, 2.0-17.1). Nonetheless, prior AP therapy was independently associated with a favorable outcome (odds ratio, 2.0; 95% confidence interval, 1.0-4.3).
CONCLUSION: Despite a higher incidence of SICH, the net benefit of intravenous tissue plasminogen activator therapy for acute ischemic stroke was greater in patients using AP drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332238     DOI: 10.1001/archneur.65.5.noc70077

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  15 in total

Review 1.  Simultaneous acute cardio-cerebral infarction: is there a consensus for management?

Authors:  Oluwaseun A Akinseye; Muhammad Shahreyar; Mark R Heckle; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2018-01

2.  Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke.

Authors:  Hen Hallevi; James C Grotta
Journal:  Arch Neurol       Date:  2008-05

3.  Initial experience with a self-expanding retrievable stent for recanalization of large vessel occlusions in acute ischemic stroke.

Authors:  Bijoy K Menon; Puneet Kochar; Andrew Ah-Seng; Mohammed A Almekhlafi; Jayesh Modi; John H Wong; Mark E Hudon; Will Morrish; Andrew M Demchuk; Mayank Goyal
Journal:  Neuroradiology       Date:  2011-01-12       Impact factor: 2.804

4.  A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.

Authors:  S M Zinkstok; M Vermeulen; J Stam; R J de Haan; Y B Roos
Journal:  Trials       Date:  2010-05-12       Impact factor: 2.279

5.  Antiplatelet therapy, but not intravenous thrombolytic therapy, is associated with postoperative bleeding complications after decompressive craniectomy for stroke.

Authors:  Patrick Schuss; Valeri Borger; Hartmut Vatter; Oliver C Singer; Volker Seifert; Erdem Güresir
Journal:  J Neurol       Date:  2013-05-28       Impact factor: 4.849

6.  Does preexisting antiplatelet treatment influence postthrombolysis intracranial hemorrhage in community-treated ischemic stroke patients? An observational study.

Authors:  William J Meurer; Heemun Kwok; Lesli E Skolarus; Eric E Adelman; Allison M Kade; Jack Kalbfleisch; Shirley M Frederiksen; Phillip A Scott
Journal:  Acad Emerg Med       Date:  2013-02       Impact factor: 3.451

7.  Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke.

Authors:  Amelia J Tomkins; Nadine Schleicher; Lucy Murtha; Manfred Kaps; Christopher R Levi; Max Nedelmann; Neil J Spratt
Journal:  Exp Transl Stroke Med       Date:  2015-01-27

Review 8.  Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta-analysis of 19 Studies.

Authors:  Shengyuan Luo; Mei Zhuang; Wutao Zeng; Jun Tao
Journal:  J Am Heart Assoc       Date:  2016-05-20       Impact factor: 5.501

9.  Increased Risk of Post-Thrombolysis Intracranial Hemorrhage in Acute Ischemic Stroke Patients with Leukoaraiosis: A Meta-Analysis.

Authors:  Qianqian Lin; Zhong Li; Rui Wei; Qingfeng Lei; Yunyun Liu; Xiaodong Cai
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

Review 10.  Reperfusion therapy in acute ischemic stroke: dawn of a new era?

Authors:  Sonu Bhaskar; Peter Stanwell; Dennis Cordato; John Attia; Christopher Levi
Journal:  BMC Neurol       Date:  2018-01-16       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.